Xyzal Liều dùng/Hướng dẫn sử dụng

The film-coated tablet must be taken orally, swallowed whole with liquid and may be taken with or without food. It is recommended to take the daily dose in one single intake.
Adults and adolescents 12 years and above: The daily recommended dose is 5 mg (1 film-coated tablet).
Elderly: Adjustment of the dose is recommended in elderly patients with moderate to severe renal impairment (see Adult patients with renal impairment as follows).
Children aged 6 to 12 years: The daily recommended dose is 5 mg (1 film-coated tablet).
Children aged less than 6 years: Not recommended to take the 5 mg tablet formulation.
Adult patients with renal impairment: The dosing intervals must be individualized according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (CL_cr) in ml/min is needed. The CL_cr (ml/min) may be estimated from serum creatinine (mg/dl) determination using the following formula: (See equation.)


Click on icon to see table/diagram/image


Dosing Adjustments for Patients with Impaired Renal Function: (See table.)


Click on icon to see table/diagram/image


Pediatric patients suffering from renal impairment: Levocetirizine is contraindicated in children 6 to 11 years of age with impaired renal function (see Contraindications). In children above 11 years with impaired renal function, the dose will have to be adjusted on an individual basis taking into account the renal clearance of the patient and his/her body weight. There are no specific data for children with renal impairment.
Patients with hepatic impairment: No dose adjustment is needed in patients with solely hepatic impairment. In patients with hepatic impairment and renal impairment, adjustment of the dose is recommended (see previous discussion on Adult patients with renal impairment).
DURATION OF USE: Intermittent allergic rhinitis (symptoms <4 days/week or during less than 4 weeks a year) has to be treated according to the disease and its history; it can be stopped once the symptoms have disappeared and can be restarted again when symptoms reappear.
In case of persistent allergic rhinitis (symptoms >4 days/week or for more than 4 weeks a year), continuous therapy can be proposed to the patient during the period of exposure to allergens.
There is clinical experience with the use of levocetirizine for treatment periods of at least 6 months. For chronic urticaria and chronic allergic rhinitis, up to one year's clinical experience is available for the racemate.